



Mauna Kea Technologies Announces Strong Presence of Cellvizio at the OESO 14th World Conference

OESO conference focuses on diseases of the esophagus, a key application for Cellvizio in Mauna Kea Technologies' core GI business

Paris, August 31, 2017 – 5.45 PM CET – Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) platform, today announced that Cellvizio will be highlighted in several presentations at the OESO The Esophagus 14th World Conference in Geneva, Switzerland from September 2-5, 2017. OESO is a scientific organization with 14,000 members from 85 countries, including leading specialists from 19 disciplines, all interested in one, single organ: the esophagus.

Sacha Loiseau, Ph.D., Founder and Chief Executive Officer of Mauna Kea Technologies, commented, “The presentations at the conference will demonstrate the value of using Cellvizio in patients suffering from GERD, Barrett’s esophagus, esophageal cancer, obesity and other diseases, along with information on its general use and cost-effectiveness compared to other technologies. We look forward to meeting customers at the conference as we continue building awareness and adoption of Cellvizio in our core GI business, particularly in the U.S. where we are implementing a customer-friendly, pay-per-use business model.”

The sessions at the OESO conference featuring presentations related to Cellvizio include:

Saturday, September 2

- Pre-Congress Session IV from 3:00 – 5:00 pm in Room 3: “Histology Training course – In vivo Histo-pathology OESO Histology Tutorial.” Satish K. Singh, MD, Associate Professor of Medicine at the Boston University School of Medicine, will present this session entirely dedicated to the use of Cellvizio for in vivo histo-pathology.

Monday, September 4

- Session 25 from 8:00 – 10:00 am in Room 4: “State of the art lectures.” Dr. Singh will highlight Cellvizio in Barrett’s esophagus in a lecture titled “Confocal laser endomicroscopy in Barrett’s esophagus.”
- Session 29 from 10:30 am – 12:30 pm in Room 2: “Barrett’s esophagus.” Hiroshi Mashimo, MD, PhD, Associate Professor of Medicine at Harvard Medical School, will address the use of Cellvizio in Barrett’s esophagus management in a presentation titled “A new look: Is in vivo confocal microscopy (Cellvizio) the new way to look at Barrett’s Esophagus?”
- Session 44 from 4:15 – 6:15 pm in Room 18: “Obesity and cancer.” Dr. Mashimo will highlight the use of Cellvizio in obese patients in a presentation titled “Confocal microscopy in the workup of the bariatric patient.”

Tuesday, September 5

- Session 47 from 8:00 – 10:00 am in Room 2: “Health Technology Assessment – Public Health in a collaborative world.” Simone Guaraldi, MD, from the National Cancer Institute in Rio de Janeiro, will compare Cellvizio to other imaging technologies in a presentation titled “Cost-effectiveness of optical endomicroscopy vs high definition white light endoscopy alone.”
- Session 48 from 8:00 – 10:00 am in Room 3: “Superficial cancers.” Dr. Mashimo will co-chair this session and highlight the use of Cellvizio in esophageal cancers in a presentation titled “Role of endoscopy, confocal microscopy, optical coherence tomography and EUS in the diagnosis of early esophageal cancers.”



About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company's flagship product, Cellvizio, has received clearance to sell a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico. For more information on Mauna Kea Technologies, visit www.maunakeatech.com

United States

Zack Kubow / Lee Roth
The Ruth Group
646-536-7020 / 7012
zkubow@theruthgroup.com lroth@theruthgroup.com

U.S. Media

Kirsten Thomas
The Ruth Group
508-280-6592
kthomas@theruthgroup.com

France and Europe

NewCap - Investor Relations
Florent Alba
+33 (0)1 44 71 94 94
maunakea@newcap.eu

Disclaimer

This press release contains forward-looking statements concerning Mauna Kea Technologies and its activities. Such forward looking statements are based on assumptions that Mauna Kea Technologies considers to be reasonable. However, there can be no assurance that the anticipated events contained in such forward-looking statements will occur. Forward-looking statements are subject to numerous risks and uncertainties including the risks set forth in the registration document of Mauna Kea Technologies registered by the French Financial Markets Authority (Autorité des marchés financiers (AMF)) on June 13, 2016 under number R.16-054 and available on the Company's website (www.maunakeatech.com), and to the development of economic situation, financial markets, and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this release are also subject to risks unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not consider material at this time. The realization of all or part of these risks could lead to actual results, financial conditions, performances or achievements by Mauna Kea Technologies that differ significantly from the results, financial conditions, performances or achievements expressed in such forward-looking statements. This press release and the information it contains do not constitute an offer to sell or to subscribe for, or a solicitation of an order to purchase or subscribe for, Mauna Kea Technologies shares in any country.